In the treatment of Carcinoid syndrome, which is caused by the endocrine and exocrine secretions of various hormones from carcinoid tumors, Octreotide targets somatostatin receptors and inhibits hormone secretions. The severe diarrhea associated with metastatic carcinoid tumors is related to elevated levels of serotonin and its metabolite, 5-HIAA. Octreotide provides Somatostatin receptor-targeted inhibition. In other words, Octreotide targets Somatostatin receptors and can regulate important cellular activity, as well as help inhibit hypersecretion of hormones, including serotonin and growth hormone.
Several mechanisms of actions have been suggested for Octreotide use in gastro-entero-pancreatic (GEP) endocrine tumours. These suggested mechanisms include the inhibition of exocrine secretion in the digestive system (eg, gastrin, serotonin), inhibition of endocrine secretion of hormones (eg, growth hormone, insulin, glucagon), modulation of biliary and GI motility, acting as a neurotransmitter, and induction of apoptosis. Five somatostatin receptor subtypes have been identified in gastro-entero-pancreatic (GEP) endocrine tumours. Octreotide is used to control hormone-mediated symptoms in GEP endocrine tumours such as insulinoma, gastrinoma, VIPoma, glucagonoma, somatostatinoma, GRFoma/acromegaly, and carcinoid tumours. Octreotide is cell cycle phase-specific (G-phase).
In the treatment of MBO (Malignant Bowel Obstruction), Octreotide acts as a potent antisecretagogue with a complex mechanism of action. Through its direct effect on intestinal smooth muscle, influx of gastric and intestinal secretions into the lumen is decreased, thus reducing intestinal distention. Octreotide also directly inhibits neurotransmission in peripheral nerves of the gastrointestinal tract, thereby decreasing peristalsis and splanchnic blood flow. When the vicious cycle of distention-secretion-distention is interrupted, bowel wall edema and ischemia decrease, reducing painful intestinal cramping and the risk for intestinal necrosis and perforation. Early use of octreotide in malignant bowel obstruction aids in the restoration and maintenance of bowel function and control of gastrointestinal symptoms.
Storage conditions: Store between 2- 8o C
Packaging: glass vials